Company Profile

ABOUT US

JIANGSU VCARE PHARMATECH CO.,LTD.(“Jiangsu Vcare”) was co-founded in 2010 by professors from China Pharmaceutical University and outstanding overseas returnees. Over our 14 years of development history, we have evolved into a leading high-tech pharmaceutical company, as well as a group company, with two core business areas including new drug R&D and CRO & CDMO services for the entire industrial chain. we currently employ over 800 employees, comprising 16 Ph.D. and approximately 200 masters, and 84% of the staff are professional and technical personnel. Our headquarters, also the R & D site covering an area of 3.3 acres with a building area of 21,000m2, is located in Biomedical Valley of Jiangbei New Area, Nanjing, which was constructed with an investment of 200 million yuan.

Jiangsu Vcare, as the parent company, focuses on the independent R&Dof newdrugs,and addressing unmet clinical needs through a differential approach. At present, there are four new drug projects in the clinical stage, includingVicagrel capsules(an oralanti-platelet drug), VC004 capsules(anoral anti-tumor targeted drug),VC005 tablets(an oral anti-inflammatory and immunomodulatory drug),and VC005 gel(a topical anti-inflammatory and immunomodulatory drug).Moreover, multiple pre-clinical projectsarebeing developedconsistently. We have established a robust pipeline of innovative treatments, with Vicagrel at the forefront, which holds significant potential for future global market competition in multiple disease areas, including cardiovascular, oncology, inflammation,autoimmunity, etc.

NanjingVcare, as a wholly-owned subsidiaryof Jiangsu Vcare, specializes in providingfullindustry chain CRO/CDMO services for pharmaceuticals, and its establishedone-stop service platform is capable of providing comprehensive support throughout the overall lifecycle of R&D and manufacturing, including chemical,pharmaceutical, and clinical researchservices. NanjingVcareis committed to providing our global customers with industry-leading and integratedservices, comprising CDMO services throughout manufacturingand supply from advanced pharmaceutical intermediates toAPIs,and CRO services throughout the process from CMC research to clinical research to registration. During the provision of services, nine advanced technology platforms with both excellent innovativeness and competitiveness can further ensure that we possess higher service quality and capability compared to other companies, moreover, our manufacturing site, covering approximately21.5 acres, enables us to maintain reliability and stability of our supply chain, and to control our manufacturing and development costs.

Our pioneeringbusiness patternenables CRO&CDMOservicesto generate revenue, and to fundthe R&Dof newdrugs, as a result, a two-wheel driving, synergistic, and self-supporting operating modelcan be established.We have successfullyraised nearly 1 billion yuan through three financing rounds between 2021 and 2023, showing that our distinctive businesspattern wasacknowledged by the capital.Moreover, we have successively set up a Jiangsu provincial enterprise academician workstation and a Nanjing postdoctoral innovation practice base and jointly established an enterprise graduate workstation collaborating with China Pharmaceutical University. We also have been selected as one of Nanjing's "unicorn" enterprises, Jiangsu Provincial Specialized and Sophisticated Small and Medium-sized Enterprises(SME), and have been selected into a Nanjing cultivation library of innovative leading enterprises. Nanjing Vcare has been ranked among China’s top 20 CRO enterprises for several consecutive years.

In the future, wewillbe consistentlydedicatedtoproviding more effectiveandmoreaccessibletreatments for patients, taking "The Better Care, The Better Medicines"as our permanent credoand "Addressing unmet clinical needs"asour core driving force. Meanwhile, we will continue to pursue thestrategic pattern of synergistic development oftwo business unitsand willprovide more professional and cost-effective solutionsfor global customs based on R&Dand guided by industrialization.

2011

In 2011, the company was rated as a private science and technology enterprise in Jiangsu Province; it was funded by the Technology Innovation Fund for Small and Medium-sized Scientific and Technological Enterprises of the Ministry of Science and Technology

2013

He was awarded the title of high-tech enterprise and small and medium-sized scientific and technological enterprise in Jiangsu Province in 2013 

2016

Established Nanjing Engineering Research and Technology Center in 2016; received funding from Jiangsu Key R & D Program (Social Development) project 

2017

In 2017, he was selected as an enterprise under the "Lantern Program" in Jiangbei New Area and established a graduate workstation for provincial enterprises; he was funded by the National "Thirteenth Five-Year Plan" Major Project 

2018

He won the third prize of Jiangsu Provincial Science and Technology Award and established the Academician Workstation of Jiangsu Enterprise in 2018

2019

In 2019, Nanjing Postdoctoral Innovation Practice Base, Southern Jiangsu National Independent Innovation Demonstration Zone and Jiangsu Provincial R & D enterprises were established to obtain the special funds for the transformation of scientific and technological achievements in Jiangsu Province